Feb 25, 2010 by Brian Orelli, PhDAn Untouched Market Waiting to Be CapturedUnfilled prescriptions are a potential boon to drug companies.
Feb 25, 2010 by Brian Orelli, PhD13 Is Pfizer's Lucky NumberInherited from Wyeth, Prevnar 13 could be a goldmine.
Feb 25, 2010 by Brian Orelli, PhDTransplanting Future RevenueBristol-Myers Squibb waits for experts to decide the fate of its kidney cancer drug.
Feb 23, 2010 by Brian Orelli, PhDIcahn Puts His Proxy Fight Where His Money IsWhich activist will Icahn be with Genzyme?
Feb 23, 2010 by Brian Orelli, PhDThe End of a Swine Flu EraYour arm will be happy; no more extra shot.
Feb 23, 2010 by Brian Orelli, PhDTriple-Teaming Cancer for Fun and ProfitPfizer, Merck and Eli Lilly set up a nonprofit, but there may be an ulterior motive.
Feb 23, 2010 by Brian Orelli, PhDThe One That Didn't Get AwayAfter some encouragement, the FDA approves Gilead's Cayston.
Feb 22, 2010 by Brian Orelli, PhDSo Long, See You in ArbitrationAfter another rejection, Johnson & Johnson and Basilea call it quits.
Feb 22, 2010 by Brian Orelli, PhDWarning: Avandia Could Cause Drool Among Trial LawyersAn unintended side effect of Glaxo's Avandia might be excessive salivation among trial lawyers.
Feb 22, 2010 by Brian Orelli, PhDA Huge Business Wrapped Up in Tiny PackagesDrug investors shouldn't forget about over-the-counter products.
Feb 19, 2010 by Brian Orelli, PhDBreathe Deep. It Might Not Be That Bad.The FDA strikes down asthma drugs, but will doctors buy in?
Feb 18, 2010 by Brian Orelli, PhDGilead Shareholders Are Whistling a Happy TuneFull data from the company's quad pill show no major issues.
Feb 18, 2010 by Brian Orelli, PhDStill Restless for an ApprovalThe FDA is like a box of chocolates: You never know what you're going to get.
Feb 17, 2010 by Brian Orelli, PhDExecute Well or You're OutGenzyme needs to show investors that it can rebuild.
Feb 17, 2010 by Brian Orelli, PhD$1.24 Billion Deal. Shares Fall 9%. That Makes Sense.Rigel gets just a little up front; investors balk.
Feb 17, 2010 by Brian Orelli, PhDThis Is Not Your Generic Cash ProductionTeva's generating cash and knows how to use it.
Feb 16, 2010 by Brian Orelli, PhDFor Blockbuster Cancer Drugs, Approvals Are the Easy PartDon't get too excited.
Feb 16, 2010 by Brian Orelli, PhDMerck Gets a Pass, for NowIts first quarter looks promising, but not as good as could be hoped.
